NCT01425814View on ClinicalTrials.gov

Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population

PHASE2CompletedINTERVENTIONAL

Enrollment

87

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

LAS100977

Dry powder inhalation,Once daily, single dose

DRUG

LAS100977

Dry powder inhalation,Once daily, single dose

DRUG

LAS100977

Dry powder inhalation,Once daily, single dose

DRUG

LAS100977

Dry powder inhalation,Once daily, single dose

DRUG

Reference

Dry powder inhalation (capsule),single dose

DRUG

Placebo

Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose

Trial Locations (8)

14050

Almirall Investigational Sites#5, Berlin

14057

Almirall Investigational Sites#2, Berlin

20354

Almirall Investigational Sites#7, Hamburg

22927

Almirall Investigational Sites#3, Großhansdorf

23552

Almirall Investigational Sites#8, Lübeck

55131

Almirall Investigational Sites#1, Mainz

60596

Almirall Investigational Sites#6, Frankfurt

65187

Almirall Investigational Sites#4, Wiesbaden

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY